Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NC 762

Next Previous
X
Search
Drug Profile

NC 762

Alternative Names: NC-762

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NextCure
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; V-set domain-containing T-cell activation inhibitor 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Malignant melanoma; Solid tumours

Highest Development Phases

  • Discontinued Breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 30 Jan 2024 NextCure terminates a phase I/II trial in Solid tumours including non-small cell lung cancer, breast cancer and ovarian cancer in USA due to the limited activity in phase I (NCT04875806)
  • 14 Dec 2023 Discontinued - Phase-I/II for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 14 Dec 2023 Discontinued - Phase-I/II for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top